Basile, V., Puglisi, S., Altieri, B., Canu, L., Libè, R., Ceccato, F. ... Terzolo, M. (2021). What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. Journal of Personalized Medicine, 11. (4). doi: 10.3390/jpm11040269
Basile, Vittoria, et al. "What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question." Journal of Personalized Medicine, vol. 11, no. 4, 2021. https://doi.org/10.3390/jpm11040269
Basile, Vittoria, Soraya Puglisi, Barbara Altieri, Letizia Canu, Rossella Libè, Filippo Ceccato, Felix Beuschlein, et al. "What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question." Journal of Personalized Medicine 11, no. 4 (2021). https://doi.org/10.3390/jpm11040269
Basile, V., et al. (2021) 'What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question', Journal of Personalized Medicine, 11(4). doi: 10.3390/jpm11040269
Basile V, Puglisi S, Altieri B, Canu L, Libè R, Ceccato F, and sur.. What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. Journal of Personalized Medicine [Internet]. 2021 April 04 [cited 2024 October 14];11(4). doi: 10.3390/jpm11040269
V. Basile, et al., "What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question", Journal of Personalized Medicine, vol. 11, no. 4, April 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:323240. [Accessed: 14 October 2024]